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Learning Objectives 
 
1.  Describe the public health burden of cardiovascular disease in the 
US and the role of cardiovascular diagnostic testing 
2.  Explain the comparative cost and cost-effectiveness of diagnostic 
technologies vs. public health interventions for reducing 
cardiovascular disease morbidity and mortality 
3.  Identify the policy implications of recent utilization growth in 
diagnostic technologies for coronary heart disease, and the drivers 
of that growth 
4.  Discuss population health implications of the ACA for 
cardiovascular disease prevention and testing 
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Epidemiology 
 
•  15.4 million adults in 
the US live with 
coronary heart disease 
(CHD) and 795,000 
have a stroke each 
year 
  
•  CHD: 6.4% of adults 
overall; 7.9% of men 
and 5.1% of women 
•  CHD affects 20% of 
persons ≥ 65 years 
 
Picture source: NHLBI 
Cardiovascular Disease (CVD) is a Major Public 
Health Challenge  
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Risk Factors for Cardiovascular Disease 
Picture sources: NIH, Doctor Murray, True Med Cost, Flight Physical, 123  RF, Daily Hiit 
 
Diabetes 
High Cholesterol 
High Blood Pressure 
Smoking 
Physical Inactivity 
Obesity 
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Morbidity and Mortality Attributable to Cardiovascular 
Disease in the United States 
 
Morbidity/Quality of Life 
 
•  CVD accounts for 18% of total lost disability-adjusted life years 
(DALYs) in developed countries 
National Health Interview Survey, 2010; Go, Circulation 2013;  WHO, Global Burden of Coronary Heart 
Disease, 2002 
 
 
Mortality 
•  CHD accounts for over 386,000 deaths 
annually (1 in 6 of all deaths) 
•  More than half of sudden cardiac 
deaths occur in people with no prior 
history of heart disease 
 
Myocardial infarction 
 
•  Nearly one million new or recurrent 
heart attacks each year 
•  Early diagnosis is important 
because treatment & preventive 
practices significantly reduce 
morbidity and mortality  
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Healthcare Utilization and Costs Attributable to Coronary 
Heart Disease are Substantial 
 
 
Healthcare utilization and costs 
 
•  CHD costs $195.2 billion in direct and indirect costs annually (2009) 
•  In 2006, Medicare spent $11.7 billion on inpatient care for CHD 
•  By 2030, medical costs for CHD (real 2010$) projected to increase ≈100% 
 
Ambulatory care 
•  In 2009, there were over 14 million 
ambulatory care visits with CHD as the 
first-listed diagnosis  
 
Hospital care 
 
•  1.3 million hospital admissions with 
CHD listed as the first diagnosis 
•  954,000 percutaneous coronary 
interventions (PCIs), 397,000 cardiac 
bypass surgeries, 1.03 million 
diagnostic cardiac catheterizations 
National Health Interview Survey, 2010; Go, Circulation 2013 
 
In Men And Women Without A History Of 
CHD, Noninvasive And Invasive Testing 
Are Central To Making A Diagnosis 
Cardiac Stress Testing 
Source of picture: NHLBI 
Clinical Decision Pathway for Patients 
Evaluated for CHD 
 
Initial Exam for Chest Pain 
Invasive Angio 
Treatment 
Cardiac Stress Testing 
No Further 
Dx or Tx 
No MI Death MI 
+
+
- 
- 
Abbreviations - Dx: Diagnosis, Tx: Treatment, MI: Myocardial Infarction 
Primary Care Physicians Routinely Manage Patients With 
Suspected or Diagnosed CHD 
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Cardiology 
Primary Care 
Invasive 
Angiography 
Stress Echo 
Nuclear Imaging 
CT Angiography 
Clinical Factors 
EKG Treadmill 
Diagnostic Tools 
Often Repeat  
Testing 
~4M Stable, Symptomatic 
Patients Suggestive of  
Coronary Disease Annually 
1 Patel et al, N Engl J Med 2010;362:886-95; COMPASS study. 
2 IMV Market Reports 
 
Obstructive CAD is not found in 
~60% patients1   
 ~$4.5B annual expenditures2 
Cost-effectiveness of Diagnostic Tests vs. 
Public Health Interventions for CHD 
  13 
Cost 
Effectiveness 
Cost 
Effectiveness 
Cost 
Effectiveness 
Cost 
Effectiveness 
Cost 
E
ffectiveness ↑ 
↑ 
↑ 
↑ 
↑ 
↑ 
↑ 
↑ 
Dominated Cost Effectiveness Ratio 
Dominant Cost Effectiveness Ratio 
- 
- 
+ 
+ 
Quality-Adjusted Survival: Heart Attack Example 
1.0 
 
 
 
 
 
 
0.5 
 
 
 
0 
U
til
ity
 W
ei
gh
t 
Treatment 
Started 
Surgery Major Heart Attack 
Death 
Asymptomatic 
Angina 
Minor 
Limitations 
Bedridden 
  15 
QALYs 
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0                          10 
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Cost-effectiveness Ratio 
Costnew policy – Costcurrent policy 
 
Effectnew policy – Effectcurrent policy 
$ 
Life years, QALYs 
CE ratio = 
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Cost-saving 
Salt reduction 
in processed 
foods 
$161,000/QALY 
Exercise ECG: 
Women 
$71,900/QALY 
Corus GES 
$51,200/QALY 
Exercise ECG: 
Men 
$32,500/QALY 
Exercise MPI 
$39,000/QALY 
Coronary CTA: 
Women 
$31,500/QALY 
Exercise 
ECHO 
$31,000/QALY 
Coronary CTA: 
Men 
$6,000-$26,000/
QALY 
Antihypertensives 
for all with 
hypertension 
$5,000-$6,000/
QALY 
Polypill for 
primary 
prevention 
Cost-effectiveness of Diagnostic Tests vs. Public Health 
Interventions for CHD 
Sources: Ladapo et al, JACC 2009; Kuntz et al, Annals 1999; Phelps et al, AHJ 2014; 
Bibbins-Domingo, NEJM 2010; Weintraub et al, Circulation 2011 
High-value Low-value 
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Public health interventions tend to be more cost-
effective but individual patients benefit from diagnostic 
tests, and diagnosis often cannot be made without them 
Challenges With Cardiac Stress Test Use: 
Clinical, Payer, and Policy Concerns 
 
 ü  1. Too much low-value, high-intensity testing  
→ less cost-effective at population level 
 
  2. Poor diagnostic accuracy → missed diagnoses 
 
  3.  Unnecessary radiation → radiation-related  
cancers 
Trend Toward Use of Increasingly Intensive 
Technologies in Patients Evaluated for CHD 
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Then 
Source of pictures: NYU School of Medicine, Bleiglass at the English language Wikipedia 
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Source of pictures: NYU School of Medicine, Bleiglass at the English language Wikipedia 
Then Now 
Trend Toward Use of Increasingly Intensive 
Technologies in Patients Evaluated for CHD 
Utilization of Cardiac Imaging Stress Tests Has 
Grown Tremendously 
 
Medicare population 
 
•  Between 1993 and 2001, 
nearly 300% increase in 
use of imaging stress tests 
(stress echocardiography, 
ECHO; myocardial 
perfusion imaging, MPI) 
•  Rose from 29 to 82 per 
1,000 beneficiaries 
•  Rate of non-imaging stress 
tests fell modestly 
•  Rate of PCI doubled from 6 
to 12 per 1,000 
beneficiaries 
22 Lucas, Circulation 2006 
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Ambulatory Care: Cardiac Stress Tests In Patients 
Without CHD, From 1993 To 2010 
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Any cardiac stress test 
Stress imaging 
Avg. 
annual 
cost in 
1993-1995 
Avg. 
annual 
cost in 
2008-2010 
All cardiac 
stress tests 
$820M $2.0B 
Stress 
imaging 
$550M $1.9B 
Source: Ladapo et al, Annals of Internal Medicine 2014 (forthcoming);  National Ambulatory 
Medical Care Survey and National Hospital Ambulatory Medical Care Survey data (1993-2010) 
24 Rozanski, JACC 2013 
Unnecessary Testing is Common 
 
Our Threshold for Testing 
Patients May be Falling 
 
•  39,515 patients undergoing 
stress MPI between 
1991-2009 at Cedars Sinai 
•  Incidence of abnormal scans 
fell from 41%→9% 
•  Incidence of ischemic scans 
fell from 30%→5%  
•  Only 3% of patients who  
did not have typical angina 
and could exercise had  
an abnormal scan 
Challenges With Cardiac Stress Test Use: 
Clinical, Payer, and Policy Concerns 
 
 ü  1. Too much low-value, high-intensity testing  
→ less cost-effective at population level 
 
  2. Poor diagnostic accuracy → missed diagnoses 
 
  3.  Unnecessary radiation → radiation-related  
cancers 
ü
Uncertainty About How to Interpret Diagnostic Test Results 
is Common 
•  Bayes’ theorem defines how pretest disease risk and diagnostic test 
performance can be used to guide interpretation of test results  
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Reverend Thomas Bayes 
Missed or 
misdiagnosed 
Correctly 
identified 
 Optimal 
care 
True 
positives 
True 
negatives 
False 
positives 
False 
negatives 
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Referral Bias Influences Diagnostic Accuracy and Test 
Interpretation 
 
•  Sometimes called “verification bias” or 
“workup bias”  
•  Occurs because higher-risk patients are 
preferentially referred to cardiac 
catheterization 
•  Bayesian methods needed to adjust 
diagnostic test performance for referral 
 
•  Studies of stress test 
performance do not adjust 
for this phenomenon so 
estimates of sensitivity and 
specificity biased 
 
 
•  Because it biases test 
performance, it may 
also bias clinical 
decision-making 
 
Referral bias 
Most studies do 
not account for 
referral  
Biases clinical 
decision-making 
Begg, Biometrics 1983 
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Cardiac Catheterization Referral Rates After Normal 
Exercise ECHO or MPI Results 
29 
Referral rates are low 
after a normal study 
•  Range of ~1% to 
5% generally 
Homogenous 
•  Geographic location 
and patient 
characteristics vary 
but little variation in 
referral rates 
 
Ladapo et al, JAHA 2013 
Cardiac Catheterization Referral Rates After Abnormal 
Exercise ECHO or MPI Results 
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Referral rates 
higher after an 
abnormal test 
•  Range of ~20% to 
50% generally 
Heterogeneity 
•  Significant 
variation in 
referral rates 
Ladapo et al, JAHA 2013 
Observed vs. True Diagnostic Performance of 
Exercise ECHO 
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Observed performance True performance 
True performance = observed performance after adjustment for referral 
Observed vs. True Diagnostic Performance of 
Exercise MPI 
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Morbidity and Mortality Attributable to Missed 
Diagnoses of CHD in the US 
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4 million patients/yr x 20% CHD prevalence x 60% false negative rate ≈  
    500,000 missed diagnoses 
 
 
    Approx. 2,200 preventable cardiac events 
Ladapo et al, under review 
Challenges With Cardiac Stress Test Use: 
Clinical, Payer, and Policy Concerns 
 
 ü  1. Too much low-value, high-intensity testing  
→ less cost-effective at population level 
 
  2. Poor diagnostic accuracy → missed diagnoses 
 
  3.  Unnecessary radiation → radiation-related  
cancers 
ü
ü
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Unnecessary Radiation Exposure is a Growing Problem 
 
Potential harms related to radiation exposure are poorly understood 
 
•  Stress MPI accounts for 22% of cumulative effective radiation from medical sources 
•  One MPI ≈ 1,000 chest x-rays ≈ 10-15 mSv 
•  Persons at risk for repeated radiation exposure, such as healthcare workers and the nuclear industry, typically restricted to 
max 100 mSv every 5 years 
 
Columbia University Medical Center 
 
•  1,097 consecutive patients, 8-10 years of 
follow-up 
•  Multiple MPIs performed in 424 patients 
(39%) 
•  Median cumulative effective dose from MPI 
was 29 mSv 
•  Median cumulative effective dose from  
medical sources was 64 mSv 
 
Medicare population 
 
•  Between 1993-2001, 34% of enrollees 
underwent repeat testing 
 
Fazel, NEJM 2009; Einstein, JAMA 2010; Gerber, Circulation 2009; Lucas, Circulation 2006; Chen, JACC 2010 
 
US nonelderly population 
 
•  952,420 adults in 5 US markets (2005-2007) 
•  Among patients undergoing cardiac imaging, 
mean cumulative dose 16.4 mSv (1.5-190 
mSv) 
•  MPI accounted for 74% of cumulative dose  
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   1. Reduce unnecessary testing 
 
   2. Improve diagnostic accuracy 
 
   3. Promote prevention/Affordable Care Act 
ü
Reducing the Population Health Burden of 
Coronary Heart Disease: Clinical, 
Professional Society, and Policy Steps 
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 Improving Quality of Care: Reducing Unnecessary Testing 
 
Appropriate use criteria 
 
•  Growing physician awareness of appropriate use criteria for diagnostic testing in patients 
suspected of having CAD 
•  ACC and United Healthcare registry reported that 34% of stress MPIs were inappropriate or of 
uncertain appropriateness 
 
Patient/Professional  
 education 
 
•  Informed     
decision-making 
•  Shared decision-making 
 
•  Professional society scrutiny 
 
Insurer policies and regulation 
 
•  Prior authorization by radiology benefits 
managers 
•  Reductions in reimbursement 
•  Medicare released national coverage 
decision requesting more evidence for 
coronary CT angiography (CTCA) 
Shaw, JACC: CV Imaging 2010; Gibbons, JACC 2008 
…Impact on health is unknown and needs to be studied 
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Improving Quality of Care: Optimizing Diagnostic Accuracy 
 
Research on diagnostic accuracy of stress testing that accounts 
for referral patterns to cardiac catheterization is needed 
 
•  Wider dissemination of accurate information about diagnostic performance 
 
Coronary CT angiography 
•  High-resolution visualization of 
coronary anatomy 
•  Limitation: Ischemic heart disease 
occurs in absence of coronary 
stenosis 
 
Blood-based gene-expression 
test for diagnosing 
obstructive CAD (Corus CAD) 
 
•  First clinically validated gene 
expression test for CAD 
•  Nondiabetic patients only 
 
  
Blood-based Gene Expression Score (GES) Measures 
Expression of 23 Genes From Peripheral Blood Cells 
Picture source: CardioDx 
41 
Presentation Title Goes Here 42 Thomas et al, Circ Card Genetics 2013 
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•  Primary Endpoint: GES performance by ROC analysis 
•  Steering Committee: Greg Thomas, MD, MPH, John McPherson, MD, Alexandra Lansky, MD, 
Szilard Voros, MD 
•  19 U.S. sites, 431 patients  
COMPASS (Coronary Obstruction Detection by Molecular Personalized  
Gene Expression) 
COMPASS Trial Design 
  44 1 - Specificity 
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Implications For Cardiovascular Health: 
Healthcare Reform and Focus on Prevention 
 
•  No more gender rating à women cannot be 
charged higher premiums than men  
•  Expansion of insurance access à more 
testing 
•  Elimination of cost-sharing for some 
preventive care 
 
•  Lower thresholds for 
prescribing statins 
•  New risk equations for 
predicting CAD events 
 
 
•  Launched by Dept of Health 
and Human Services in 2011 
to prevent 1 million heart 
attacks and strokes by 2017 
•  ABCS - Aspirin, Blood-
pressure control, Cholesterol 
management, and Smoking 
cessation 
 
 
 
Affordable Care Act 
ACC/AHA 
Cholesterol 
Guidelines 
 
 
Conclusions 
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•  Population health burden of cardiovascular disease is substantial, 
but many public health interventions and diagnostic tests are cost-
effective 
•  Cardiac stress testing, the principal test used to diagnose CHD, may 
be overused, inaccurate, and expose patients to unnecessary 
radiation 
•  Clinical guidelines, new technologies, and recent policy changes 
may improve the effective use of diagnostic technologies and reduce 
the population health burden of CHD 
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Thank you! 
 
joseph.ladapo@nyumc.org 
646-501-2561 
